TABLE 1.
Patient characteristics
| Characteristic | All | Partial responders | Primary progressors |
|---|---|---|---|
| (n = 69) | (n = 41) | (n = 28) | |
| Initial diagnosis | |||
| Age, years, median (range) | 64 (24–82) | 60 (24–82) | 67.5 (33–81) |
| Sex, male/female, n | 33/36 | 17/24 | 16/12 |
| LDH >UNL, n (%) a | 55 (80) | 32 (78) | 23 (82) |
| ECOG PS 2–4, n (%) b | 19 (28) | 11 (27) | 8 (29) |
| Ann Arbor stage III/IV, n (%) | 48 (70) | 25 (61) | 23 (82) |
| Extranodal disease (>1), n (%) | 29 (42) | 15 (37) | 14 (50) |
| IPI score, n (%) c | |||
| 0–2 | 26 (38) | 20 (49) | 6 (21) |
| 3–5 | 43 (62) | 21 (51) | 22 (79) |
| Immunohistochemistry, n (%) | |||
| GCB/non‐GCB d | 28/35 | 14/23 | 14/12 |
| MYC expression | 37 (61) | 20 (57) | 17 (65) |
| BCL2 expression | 44 (73) | 27 (79) | 17 (65) |
| MYC and BCL2 expression | 25 (42) | 15 (44) | 10 (40) |
| Fluorescence in situ hybridization, n (%) | |||
| MYC rearrangement | 8 (19) | 1 (3.8) | 7 (43) |
| MYC and BCL2 rearrangements | 3 (6.7) | 0 (0) | 3 (17) |
| Primary refractory disease | |||
| CNS relapse, n (%) e | 13 (19) | 8 (20) | 5 (18) |
| IPI score, n (%) | |||
| 0–2 | 43 (62) | 30 (73) | 13 (46) |
| 3–5 | 26 (38) | 11 (27) | 15 (54) |
a
LDH, lactate dehydrogenase; ULN, upper limit of normal.
b
ECOG PS, eastern cooperative oncology group performance status.
c
IPI, international prognostic index.
d
GCB, germinal center B‐cell‐like.
e
CNS, central nervous system.